Overview

Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

Status:
Recruiting
Trial end date:
2024-07-28
Target enrollment:
Participant gender:
Summary
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis - CALLIPER
Phase:
Phase 2
Details
Lead Sponsor:
Immunic AG
Treatments:
Calcium